100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Trump Says Anthropic No Longer Seen as National Security Threat 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
WALTHAM, Mass., Jan. 26, 2016 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday February 9, 2016 at 3:30PM EST during the conference’s Regenerative Medicine track at the Waldorf Astoria in New York, NY. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be available on Histogenics’ website for 30 days following the conference.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
